These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9647342)

  • 1. The role of acarbose in the treatment of non-insulin-dependent diabetes mellitus.
    Hanefeld M
    J Diabetes Complications; 1998; 12(4):228-37. PubMed ID: 9647342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
    Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
    J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials.
    Scheen AJ
    Diabetes Metab; 1998 Sep; 24(4):311-20. PubMed ID: 9805641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study.
    Lam KS; Tiu SC; Tsang MW; Ip TP; Tam SC
    Diabetes Care; 1998 Jul; 21(7):1154-8. PubMed ID: 9653611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.
    Chiasson JL; Josse RG; Hunt JA; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH; Wolever TM
    Ann Intern Med; 1994 Dec; 121(12):928-35. PubMed ID: 7734015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients.
    Bayraktar M; Van Thiel DH; Adalar N
    Diabetes Care; 1996 Mar; 19(3):252-4. PubMed ID: 8742572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No relationship between carbohydrate intake and effect of acarbose on HbA1c or gastrointestinal symptoms in type 2 diabetic subjects consuming 30-60% of energy from carbohydrate.
    Wolever TM; Chiasson JL; Josse RG; Hunt JA; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH
    Diabetes Care; 1998 Oct; 21(10):1612-8. PubMed ID: 9773719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acarbose for the treatment of type II diabetes: the results of a Canadian multi-centre trial.
    Josse RG
    Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S167-72. PubMed ID: 8529510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes.
    Wolever TM; Chiasson JL; Josse RG; Hunt JA; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH
    Int J Obes Relat Metab Disord; 1997 Sep; 21(9):756-63. PubMed ID: 9376887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New oral therapies for type 2 diabetes.
    Purnell JQ; Hirsch IB
    Am Fam Physician; 1997 Nov; 56(7):1835-42. PubMed ID: 9371013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. alpha-Glucosidase inhibitors in diabetes: efficacy in NIDDM subjects.
    Toeller M
    Eur J Clin Invest; 1994 Aug; 24 Suppl 3():31-5. PubMed ID: 8001625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in the treatment of type II diabetes mellitus.
    Baliga BS; Fonseca VA
    Am Fam Physician; 1997 Feb; 55(3):817-24. PubMed ID: 9048504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus.
    Bressler R; Johnson DG
    Arch Intern Med; 1997 Apr; 157(8):836-48. PubMed ID: 9129543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acarbose: an alpha-glucosidase inhibitor.
    Martin AE; Montgomery PA
    Am J Health Syst Pharm; 1996 Oct; 53(19):2277-90; quiz 2336-7. PubMed ID: 8893066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience with acarbose: results of a Canadian multicentre study.
    Rodger NW; Chiasson JL; Josse RG; Hunt JA; Palmason C; Ross SA; Ryan EA; Tan MH; Wolever TM
    Clin Invest Med; 1995 Aug; 18(4):318-24. PubMed ID: 8549019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acarbose for non-insulin-dependent diabetes mellitus.
    Drug Ther Bull; 1994 Jul; 32(7):51-3. PubMed ID: 7635034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New agents available for the treatment of diabetes.
    Miller EC
    Home Care Provid; 1996; 1(6):312-4. PubMed ID: 9188302
    [No Abstract]   [Full Text] [Related]  

  • 19. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44).
    Holman RR; Cull CA; Turner RC
    Diabetes Care; 1999 Jun; 22(6):960-4. PubMed ID: 10372249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of acarbose in the prevention and treatment of hypoglycaemia.
    Lefebvre PJ; Scheen AJ
    Eur J Clin Invest; 1994 Aug; 24 Suppl 3():40-4. PubMed ID: 8001627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.